About

Company description

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by breath-based diagnostics, through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.

Quick facts

Sales markets Africa; Asia; Australia; Central/South America; Eastern Europe; Middle East; North America; Western Europe
Primary business activity Contract Manufacturer
Affiliated categories: Analysis |Contract Research |Lab service & equipment More

Upcoming events

14 may 2024

Vitafoods Europe 2024

14 - 16 May 2024 - Geneva, Switzerland Visit us at stand P254 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

28 nov 2023

Fi Europe

28 - 30 Nov 2023 Frankfurt, Germany We were at stand 3.1A182 See our Exhibitor Profile   See full Exhibitor List

News about Owlstone Ltd

OMED Health Featured on BBC Click

23 Jun 2023

OMED Health Featured on BBC Click

We are delighted to see our CEO Billy Boyle featured on BBC Click’s program discussing how breath analysis can revolutionize monitoring technology to empower patients and their doctors to improve healthcare decision-making.

Read more

23 Jun 2023

Owlstone Medical Launches OMED Health

Owlstone Medical launches OMED Health to enable patients to better understand their gut microbiome and manage their digestive health.

Read more

Categories affiliated with Owlstone Ltd

Owlstone Ltd

Contact information

Address

Telephone

Website

View all contact information